利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.023 秒)

    PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS
    12.
    发明授权
    PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS 有权
    吡唑并嘧啶AS PI3K抑制剂脂质激酶

    公开(公告)号：EP2081933B1

    公开(公告)日：2011-03-23

    申请号：EP07818515.4

    申请日：2007-09-27

    申请人： Novartis AG

    发明人： IMBACH, Patricia ,  STAUFFER, Frédéric ,  FURET, Pascal ,  CAPRARO, Hans-Georg

    IPC分类号： C07D487/04

    CPC分类号： C07D487/04

    摘要： The invention relates to novel - at least 3,5-disubstituted - pyrazolo[1,5-a]pyrimidines of the formula (I), wherein the symbols R1 to R4 are as defined in the specification, tautomers thereof or N-oxides thereof, or (preferably pharmaceutically acceptable) salts thereof, or hydrates or solvates thereof, as well as to related embodiments. The compounds are useful inter alia as protein kinase inhibitors, and thus e.g. useful in the treatment of diseases that respond to an inhibition of kinases of the PI3-kinase-related protein kinase family, especially lipid kinases and/or PI3 kinase (PI3K) and/or mTOR and/or DNA protein kinase and/or ATM and/or ATR and/or hSMG-1.

    IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS
    14.
    发明公开
    IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS 有权
    2-甲基-2- [4-（3-甲基-2-氧代-8-喹啉-3-基-2,3-二氢-1H-咪唑并[4,5-C]中间体） - 苯基]丙酸乙酯脂质体酶

    公开(公告)号：EP1888578A2

    公开(公告)日：2008-02-20

    申请号：EP06753710.0

    申请日：2006-05-18

    申请人： Novartis AG ,  NOVARTIS-PHARMA GMBH

    发明人： GARCIA-ECHEVERRIA, Carlos ,  STAUFFER, Frédéric ,  FURET, Pascal

    IPC分类号： C07D471/04 ,  A61K31/4188 ,  A61P35/00 ,  A61P29/00

    CPC分类号： C07D471/04

    摘要： The invention relates to novel organic compounds of formula (I) processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof - alone or in combination with one or more other pharmaceutically active compounds - for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease.

    PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS
    18.
    发明公开
    PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS 有权
    吡唑并嘧啶AS PI3K抑制剂脂质激酶

    公开(公告)号：EP2081933A1

    公开(公告)日：2009-07-29

    申请号：EP07818515.4

    申请日：2007-09-27

    申请人： Novartis AG

    发明人： IMBACH, Patricia ,  STAUFFER, Frédéric ,  FURET, Pascal ,  CAPRARO, Hans-Georg

    IPC分类号： C07D487/04

    CPC分类号： C07D487/04

    摘要： The invention relates to novel - at least 3,5-disubstituted - pyrazolo[1,5-a]pyrimidines of the formula (I), wherein the symbols R1 to R4 are as defined in the specification, tautomers thereof or N-oxides thereof, or (preferably pharmaceutically acceptable) salts thereof, or hydrates or solvates thereof, as well as to related embodiments. The compounds are useful inter alia as protein kinase inhibitors, and thus e.g. useful in the treatment of diseases that respond to an inhibition of kinases of the PI3-kinase-related protein kinase family, especially lipid kinases and/or PI3 kinase (PI3K) and/or mTOR and/or DNA protein kinase and/or ATM and/or ATR and/or hSMG-1.